Context Therapeutics Stock Price Prediction

CNTX Stock  USD 1.52  0.02  1.33%   
At this time, the relative strength index (RSI) of Context Therapeutics' share price is approaching 36 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Context Therapeutics, making its price go up or down.

Oversold Vs Overbought

36

 
Oversold
 
Overbought
The successful prediction of Context Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Context Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Context Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.08)
EPS Estimate Current Year
(0.53)
EPS Estimate Next Year
(0.31)
Wall Street Target Price
7.7
EPS Estimate Current Quarter
(0.10)
Using Context Therapeutics hype-based prediction, you can estimate the value of Context Therapeutics from the perspective of Context Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Context Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Context because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Context Therapeutics after-hype prediction price

    
  USD 1.59  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Context Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Context Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.102.046.79
Details
Naive
Forecast
LowNextHigh
0.031.586.34
Details
4 Analysts
Consensus
LowTargetHigh
3.373.704.11
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.14-0.13-0.12
Details

Context Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Context Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Context Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Context Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Context Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Context Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Context Therapeutics' historical news coverage. Context Therapeutics' after-hype downside and upside margins for the prediction period are 0.08 and 6.34, respectively. We have considered Context Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
1.52
1.59
After-hype Price
6.34
Upside
Context Therapeutics is very risky at this time. Analysis and calculation of next after-hype price of Context Therapeutics is based on 3 months time horizon.

Context Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Context Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Context Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Context Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.63 
4.75
  0.07 
 0.00  
5 Events / Month
14 Events / Month
In about 5 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
1.52
1.59
4.61 
4,318  
Notes

Context Therapeutics Hype Timeline

Context Therapeutics is currently traded for 1.52. The entity has historical hype elasticity of 0.07, and average elasticity to hype of competition of 0.0. Context is anticipated to increase in value after the next headline, with the price projected to jump to 1.59 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 4.61%, whereas the daily expected return is currently at -0.63%. The volatility of related hype on Context Therapeutics is about 9.223372036854776E16%, with the expected price after the next announcement by competition of 1.52. Context Therapeutics currently holds about 42.92 M in cash with (21.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. Given the investment horizon of 90 days the next anticipated press release will be in about 5 days.
Check out Context Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Context Therapeutics Related Hype Analysis

Having access to credible news sources related to Context Therapeutics' direct competition is more important than ever and may enhance your ability to predict Context Therapeutics' future price movements. Getting to know how Context Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Context Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
TERNTerns Pharmaceuticals 0.03 11 per month 0.00 (0.07) 6.02 (5.96) 34.09 
AMLXAmylyx Pharmaceuticals 0.14 8 per month 4.11  0.27  10.06 (6.13) 33.56 
ABOSAcumen Pharmaceuticals(0.04)8 per month 0.00 (0.07) 7.52 (6.78) 28.07 
INZYInozyme Pharma(0.17)9 per month 0.00 (0.31) 5.07 (7.92) 16.62 
XFORX4 Pharmaceuticals 0.02 8 per month 0.00 (0.04) 8.82 (10.61) 62.35 
SPROSpero Therapeutics 0.01 9 per month 0.00 (0.15) 3.79 (4.58) 14.92 
BOLTBolt Biotherapeutics 0.01 7 per month 0.00 (0.09) 4.84 (4.48) 14.96 
CHRSCoherus BioSciences 0.01 10 per month 4.63 (0.02) 8.96 (6.94) 35.71 
GRCLGracell Biotechnologies 0.00 0 per month 6.35  0.15  16.34 (6.25) 52.11 
NLTXNeoleukin Therapeutics(0.14)1 per month 0.00 (0.08) 4.05 (3.53) 27.84 
DAWNDay One Biopharmaceuticals 0.27 10 per month 2.77 (0.05) 3.84 (3.69) 11.44 
VECTVectivBio Holding AG 0.06 7 per month 0.88  0.19  5.61 (3.08) 39.30 
NXTCNextCure(0.04)5 per month 0.00 (0.15) 5.22 (6.37) 21.68 
CTMXCytomX Therapeutics(0.06)9 per month 0.00 (0.06) 6.25 (5.22) 20.61 
ASMBAssembly Biosciences 0.06 5 per month 4.39 (0.01) 8.79 (5.34) 21.34 
ZURAZura Bio Limited(0.21)9 per month 0.00 (0.10) 7.95 (7.94) 26.70 
ANNXAnnexon(0.02)10 per month 0.00 (0.06) 6.98 (5.26) 23.00 
ICVXIcosavax(0.11)1 per month 4.56  0.13  10.22 (6.79) 38.57 
INABIn8bio Inc(0.03)6 per month 0.00 (0.03) 6.67 (11.54) 109.03 
WVEWave Life Sciences 0.21 7 per month 3.06  0.16  10.86 (6.00) 82.93 

Context Therapeutics Additional Predictive Modules

Most predictive techniques to examine Context price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Context using various technical indicators. When you analyze Context charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Context Therapeutics Predictive Indicators

The successful prediction of Context Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Context Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Context Therapeutics based on analysis of Context Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Context Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Context Therapeutics's related companies.
 2022 2023 2024 (projected)
Current Ratio11.83.835.21
Net Debt To EBITDA2.390.580.55

Story Coverage note for Context Therapeutics

The number of cover stories for Context Therapeutics depends on current market conditions and Context Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Context Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Context Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Context Therapeutics Short Properties

Context Therapeutics' future price predictability will typically decrease when Context Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Context Therapeutics often depends not only on the future outlook of the potential Context Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Context Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding16 M
Cash And Short Term Investments14.4 M

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.